secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibrx Biosciences, Inc. (INBX)
CIK:        0002007919
Form:       8-K
Filed at:   2025-04-01T23:59:59+00:00
Accession:  0002007919-25-000028
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Inhibrx promotes David Matly to President; CSO Eckelman resigns
---------------------------------------------------------------

- David J. Matly appointed President effective April 1, 2025, adding to his role as EVP, Chief Commercial and Business Development Officer.
- Mark Lappe remains CEO and Chair but no longer holds President title; Matly's base salary increased to $601,670.
- Matly granted 50,000 stock options vesting over four years under the company's equity plan.
- Brendan P. Eckelman resigned as EVP, Chief Scientific Officer effective March 31, 2025, to found a new private biotech.
- Company accelerated vesting of 50,000 of Eckelman's outstanding options and extended post-termination exercise period to October 1, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2007919/000200791925000028/0002007919-25-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2007919/000200791925000028/inhibrx-20250331.htm
  HTML page:      https://secwatch.observer/filing/0002007919-25-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer